Condition: Prostate Cancer Metastatic · Sponsor: Abramson Cancer Center at Penn Medicine
Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a clinical or research biopsy will be compared to imaging measures, if available.
This description comes directly from the study's public registry record.
Erin Schubert, BA · 215-573-6569 · erin.schubert@pennmedicine.upenn.edu
Ashley Veronsky, BA · 215-898-4346 · ashley.veronsky@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| University of Pennsylvania Hospital | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05242744